Previous Close | 36.57 |
1-Year Change | 97.25% |
6-Months Change | 52.76% |
3-Months Change | 59.76% |
Moving Avg (50d) | 35.204 |
Moving Avg (200d) | 25.965 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.972B |
Beta (3-Years) | 0.88 |
Revenue Growth (ttm) | 233.18% |
Net Profit Margin (ttm) | -988.11% |
Return On Assets (ttm) | -30.33% |
EPS (ttm) | -5.42 |
PE Ratio (ttm) | -6.75 |
Dividend Yield | % |
Asset Description: | AnaptysBio, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-17 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
37.301 | 38.398 | 39.13 | 40.227 | 42.055 | 43.884 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |